Drug intelligence / Profile preview

mIgG2a-SG3249

Development stage: Preclinical
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

mIgG2a-SG3249 is an **antibody-drug conjugate (ADC)** consisting of a mouse IgG2a isotype antibody non-specifically conjugated to the cytotoxic payload **SG3249 (tesirine)**, a pyrrolobenzodiazepine (PBD) dimer. The construct serves as a negative control in preclinical studies investigating specificity and efficacy of targeted ADCs. The SG3249 payload exerts its effect through DNA cross-linking, leading to cell death. This ADC is not intended as a therapeutic agent but as a control to evaluate target specificity and off-target effects in models of T cell malignancies, where it demonstrates minimal cytotoxic activity due to lack of target recognition[1][4].

Other names: MIGG2A-SG3249MIGG-2A-SG3249MIGG 2A-SG3249

Targets

DNA

Beyond the preview

Go deeper on mIgG2a-SG3249.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mIgG2a-SG3249.

Explore the full profile